359 reports of this reaction
2.3% of all AGALSIDASE BETA reports
#8 most reported adverse reaction
VOMITING is the #8 most commonly reported adverse reaction for AGALSIDASE BETA, manufactured by Genzyme Corporation. There are 359 FDA adverse event reports linking AGALSIDASE BETA to VOMITING. This represents approximately 2.3% of all 15,654 adverse event reports for this drug.
Patients taking AGALSIDASE BETA who experience vomiting should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VOMITING is a less commonly reported adverse event for AGALSIDASE BETA, but still significant enough to appear in the safety profile.
In addition to vomiting, the following adverse reactions have been reported for AGALSIDASE BETA:
The following drugs have also been linked to vomiting in FDA adverse event reports:
VOMITING has been reported as an adverse event in 359 FDA reports for AGALSIDASE BETA. This does not prove causation, but indicates an association observed in post-market surveillance data.
VOMITING accounts for approximately 2.3% of all adverse event reports for AGALSIDASE BETA, making it a notable side effect.
If you experience vomiting while taking AGALSIDASE BETA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.